- Home
- CGEN vs DMO Comparison
CGEN vs DMO Comparison
Compare CGEN & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- DMO
- Stock Information
- Founded
- CGEN 1993
- DMO 2009
- Country
- CGEN Israel
- DMO United States
- Employees
- CGEN N/A
- DMO N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- DMO Trusts Except Educational Religious and Charitable
- Sector
- CGEN Health Care
- DMO Finance
- Exchange
- CGEN Nasdaq
- DMO Nasdaq
- Market Cap
- CGEN 125.3M
- DMO 136.8M
- IPO Year
- CGEN 2000
- DMO N/A
- Fundamental
- Price
- CGEN $1.65
- DMO $11.97
- Analyst Decision
- CGEN
- DMO
- Analyst Count
- CGEN 0
- DMO 0
- Target Price
- CGEN N/A
- DMO N/A
- AVG Volume (30 Days)
- CGEN 324.9K
- DMO 49.6K
- Earning Date
- CGEN 11-10-2025
- DMO 01-01-0001
- Dividend Yield
- CGEN N/A
- DMO 12.06%
- EPS Growth
- CGEN N/A
- DMO N/A
- EPS
- CGEN N/A
- DMO N/A
- Revenue
- CGEN $6,903,000.00
- DMO N/A
- Revenue This Year
- CGEN N/A
- DMO N/A
- Revenue Next Year
- CGEN $208.08
- DMO N/A
- P/E Ratio
- CGEN N/A
- DMO N/A
- Revenue Growth
- CGEN N/A
- DMO N/A
- 52 Week Low
- CGEN $1.13
- DMO $10.00
- 52 Week High
- CGEN $2.66
- DMO $11.80
- Technical
- Relative Strength Index (RSI)
- CGEN 46.42
- DMO 51.30
- Support Level
- CGEN $1.54
- DMO $11.85
- Resistance Level
- CGEN $1.79
- DMO $12.03
- Average True Range (ATR)
- CGEN 0.11
- DMO 0.09
- MACD
- CGEN -0.01
- DMO 0.00
- Stochastic Oscillator
- CGEN 34.62
- DMO 64.98
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.